Abstract: A medicine administration tool configured for use in a transocular iontophoresis device for forming an electric circuit between a first electrode and a second electrode and supplying medicine to an eyeball, includes: a tubular member having a first lower end configured to face the eyeball; an inner member having a second lower end configured to face the eyeball, the inner member being accommodated in a space of the tubular member and forming a medicine accommodating chamber for accommodating the medicine between the inner member and the tubular member; and a support member movably supporting the inner member with respect to the tubular member.

Abstract: Provided is a silicone contact lens having surface hydrophilicity and surface lubricity. It has been confirmed that a silicone contact lens including, on its surface, a graft polymer chain derived from a polyoxyethylene compound having a plurality of hydroxyl groups at a terminal thereof has surface hydrophilicity and surface lubricity.

Abstract: Provided is a silicone contact lens having surface hydrophilicity and surface lubricity. The silicone contact lens includes, on its surface, a graft polymer chain derived from a branched polyoxyethylene compound represented by the formula (1): where n represents from 3 to 1,150, a represents 0 or 2, and R1 represents a hydrogen atom or a methyl group.

Abstract: Provided is an ophthalmic solution of which preservative component, hexamethylene biguanide, contained therein is inhibited from being adsorbed on soft contact lenses and eye droppers. The ophthalmic solution contains, at a specific ratio, (A) hydroxypropyl methylcellulose having 28.0 to 30.0 mass % methoxy groups and 7.0 to 12.0 mass % hydroxypropoxy groups, both with respect to the total amount of the hydroxypropyl methylcellulose, at a methoxy group/hydroxypropoxy group ratio of 2.5 to 4.0 by mass, wherein a 2 mass % aqueous solution of the hydroxypropyl methylcellulose at 20° C. has a viscosity of 50 to 4000 mPa·s; (B) sodium chloride or potassium chloride; (C) hexamethylene biguanide or a salt thereof; (D) 2-methacryloyloxyethyl phosphorylcholine/butyl methacrylate copolymer; and (E) water.

Abstract: Provided is a tear lipid layer stabilizer that is capable of stabilizing a tear lipid layer and allowing the tear lipid layer to sufficiently spread over a corneal surface, to thereby prevent the evaporation of a tear aqueous layer on the corneal surface, and hence is suitable for amelioration, alleviation, or treatment of evaporative dry eye symptoms caused by Meibomian gland dysfunction, an ophthalmic solution having blended therein the tear lipid layer stabilizer, and a tear lipid layer-stabilizing method using the tear lipid layer stabilizer. The tear lipid layer stabilizer includes a copolymer that has a weight-average molecular weight of from 10,000 to 5,000,000, and contains 10 mol % to 90 mol % of a constituent unit (A) based on 2-(meth)acryloyloxyethyl phosphorylcholine and 90 mol % to 10 mol % of a constituent unit (B) based on an alkyl group-containing (meth)acrylic monomer.

Abstract: Provided by the present invention is a corrigent composed of a copolymer having a weight average molecular weight of 10,000-5,000,000 and comprising 10-90 mol % of a constitution unit based on 2-(meth)acryloyloxyethylphosphoryl choline, and 90-10 mol % of a (meth)acrylic monomer containing an alkyl group, a (meth)acrylic monomer containing a quaternary ammonium group and a constitution unit based on a (meth)acrylamide monomer. The present invention also provides a composition for mouth cavity containing the corrigent.

Abstract: Provided is a silicone contact lens having surface hydrophilicity and surface lubricity. It has been confirmed that a silicone contact lens including, on its surface, a graft polymer chain derived from a polyoxyethylene compound having a plurality of hydroxyl groups at a terminal thereof has surface hydrophilicity and surface lubricity.

Abstract: Provided is a silicone contact lens having surface hydrophilicity and surface lubricity. The silicone contact lens includes, on its surface, a graft polymer chain derived from a branched polyoxyethylene compound represented by the formula (1): where n represents from 3 to 1,150, a represents 0 or 2, and R1 represents a hydrogen atom or a methyl group.

Abstract: An oral composition for reducing dentinal hypersensitivity according to the present invention comprises a phosphorylcholine-containing polymer as an active ingredient. A general consumer can use the oral composition routinely in various forms. The oral composition is brought into contact with an oral cavity of a user to reduce the dentinal hypersensitivity.

Abstract: Provided is a tear lipid layer stabilizer that is capable of stabilizing a tear lipid layer and allowing the tear lipid layer to sufficiently spread over a corneal surface, to thereby prevent the evaporation of a tear aqueous layer on the corneal surface, and hence is suitable for amelioration, alleviation, or treatment of evaporative dry eye symptoms caused by Meibomian gland dysfunction, an ophthalmic solution having blended therein the tear lipid layer stabilizer, and a tear lipid layer-stabilizing method using the tear lipid layer stabilizer. The tear lipid layer stabilizer includes a copolymer that has a weight-average molecular weight of from 10,000 to 5,000,000, and contains 10 mol % to 90 mol % of a constituent unit (A) based on 2-(meth)acryloyloxyethyl phosphorylcholine and 90 mol % to 10 mol % of a constituent unit (B) based on an alkyl group-containing (meth)acrylic monomer.

Abstract: Provided is a drug sustained-releasing medical contact lens in which a component that is water-insoluble and has pharmacological activity is retained to impart drug sustained-releasability, and which is excellent in oxygen permeability. It has been found that a drug sustained-releasing medical contact lens containing a specific amount of each of a silicone-based polymer having a specific structure and a drug having a specific solubility can achieve the above-mentioned contact lens.

Abstract: Provided is a biofilm formation-preventing agent that improves the sustainability of an effect of a drug, and keeps an oral environment satisfactory in a sustainable manner, without an increase in drug concentration or treatment time to prevent the maturation of dental plaque into a biofilm, and a composition for oral use containing the biofilm formation-preventing agent. More specifically, the biofilm formation-preventing agent includes a copolymer having a weight-average molecular weight of from 10,000 to 5,000,000 and containing: 10 mol % to 90 mol % of a constituent unit (A) based on 2-(meth) acryloyloxyethyl phosphorylcholine; and 90 mol % to 10 mol % of at least one kind of constituent unit selected from the group consisting of a constituent unit (B1) based on an alkyl group-containing (meth) acrylic monomer, a constituent unit (B2) based on a quaternary ammonium group-containing (meth) acrylic monomer, and a constituent unit (B3) based on a (meth) acrylamide-based monomer.

Abstract: Provided by the present invention is a corrigent composed of a copolymer having a weight average molecular weight of 10,000-5,000,000 and comprising 10-90 mol % of a constitution unit based on 2-(meth)acryloyloxyethylphosphoryl choline, and 90-10 mol % of a (meth)acrylic monomer containing an alkyl group, a (meth)acrylic monomer containing a quaternary ammonium group and a constitution unit based on a (meth)acrylamide monomer. The present invention also provides a composition for mouth cavity containing the corrigent.

Abstract: Provided is an ophthalmic solution for treatment or prevention of lid wiper epitheliopathy, which is capable of imparting sufficient lubricity to a corneal surface or a soft contact lens surface. It has been found that the above-mentioned object can be achieved by an ophthalmic solution containing, at a specific ratio, a copolymer having a structure having three kinds of different constituent units at a specific ratio.

Abstract: An oral composition for reducing dentinal hypersensitivity according to the present invention comprises a phosphorylcholine-containing polymer as an active ingredient. A general consumer can use the oral composition routinely in various forms. The oral composition is brought into contact with an oral cavity of a user to reduce the dentinal hypersensitivity.

Abstract: Provided is an ophthalmic solution of which preservative component, hexamethylene biguanide, contained therein is inhibited from being adsorbed on soft contact lenses and eye droppers. The ophthalmic solution contains, at a specific ratio, (A) hydroxypropyl methylcellulose having 28.0 to 30.0 mass % methoxy groups and 7.0 to 12.0 mass % hydroxypropoxy groups, both with respect to the total amount of the hydroxypropyl methylcellulose, at a methoxy group/hydroxypropoxy group ratio of 2.5 to 4.0 by mass, wherein a 2 mass % aqueous solution of the hydroxypropyl methylcellulose at 20° C. has a viscosity of 50 to 4000 mPa·s; (B) sodium chloride or potassium chloride; (C) hexamethylene biguanide or a salt thereof; (D) 2-methacryloyloxyethyl phosphorylcholine/butyl methacrylate copolymer; and (E) water.